寄托天下
查看: 5511|回复: 36
打印 上一主题 下一主题

[感想日志] 【备考日志】草莓酱拌饭小组 BY Donna [复制链接]

声望
0
寄托币
14
注册时间
2012-7-26
精华
0
帖子
0
跳转到指定楼层
楼主
发表于 2009-10-7 22:38:52 |只看该作者 |倒序浏览
本帖最后由 Donna.# 于 2009-10-8 08:55 编辑

我最近一直在准备aw, 应该有近一个半月啦, 最近突然悟出来一个理:aw不是简简单单的套用模板, 借用几个用滥了的例子,那样做是得不到很高的分数的, 充其量也是够用罢了。总之,踏踏实实的准备aw是“王道”!
  我对A的理解:
A相对于I确实容易,逻辑错误还是容易指出的。刚写完第一遍A时,感觉还可以,但是写着写着,再回头看就有种“腻”的感觉, 真是满眼都是模板句!太没新意啦!!!我要是ETS考官我也晕,都一样啊。。。所以, 我想用自己的话,表明我自己的逻辑,而不是马马虎虎, 应付AW。
  我对I的理解:
I是我最都头疼的了,我现在真是一篇写不出来,狂惧啊!我想我是素材积累的太少了,脑子里没有,肚子里空空,拿啥写啊?我想好好把单词再背背,至少把人文社科的英文书每样都看两本,多看, 多思考! 并且每周按时完成组里的任务,坚持写AW,这样每天一点点的进步,我相信量变终会达到质变的!
  为了飞跃重洋的梦想, 我会为之努力奋斗的!!!
请组长接收我~
回应
0

使用道具 举报

Rank: 3Rank: 3

声望
52
寄托币
812
注册时间
2009-10-2
精华
0
帖子
11
沙发
发表于 2009-10-8 17:02:11 |只看该作者
:handshake

使用道具 举报

Rank: 9Rank: 9Rank: 9

声望
758
寄托币
11696
注册时间
2004-8-28
精华
11
帖子
1564

Taurus金牛座 荣誉版主 AW活动特殊奖 AW作文修改奖 IBT Smart

板凳
发表于 2009-10-8 23:06:56 |只看该作者
请仔细阅读入组申请条件:)

务必写上awintro 读后感~
加上以后再通知我吧~fighting~
No more words. No more comments.

我想离开。这个浮华的世界。

行走在崩溃的边缘············

使用道具 举报

声望
0
寄托币
14
注册时间
2012-7-26
精华
0
帖子
0
地板
发表于 2009-10-9 10:38:29 |只看该作者

【备考日志】草莓酱拌饭小组 BY Donna

本帖最后由 Donna.# 于 2009-10-9 10:48 编辑

组长说的甚是,我又看了一遍ETS的官方指导材料,还真有写以前没体会到得东东~
对一休我一直是“敬畏”的心态,在新东方上作文课后依然如此,老师确也讲了不少写作文的技巧,但大都范范,所以我主要写一下对一休的感悟啦。以下的一段是截取自ETS,从中可以找的我们写一休的思路过程。

What, precisely, is the central issue?(抓中心)


Do I agree with all or with any part of the claim? Why or why not(立position)


Does the claim make certain assumptions? If so, are they reasonable?(有前提吗)


Is the claim valid only under certain conditions? If so, what are they?(顺藤摸瓜,局限否)


Do I need to explain how I interpret certain terms or concepts used in the claim?(表述自己的理解)


If I take a certain position on the issue, what reasons support my position?(找position的分析点,观点)


What examples—either real or hypothetical—could I use to illustrate those reasons and advancemy point of view? Which examples are most compelling?(找各观点的理由,例子)


  要是将每一道题都进行如此这般分析,势必在逻辑上有所提高,在加上平时的思辨积累是一定有突破的!而且这段话也提示了我们怎样写提纲。这里的抓中心很重要,这决定是否自己跑偏!立position,根据ETS的说法,是完全赞成、反对,部分赞成、反对。。。任何立场都ok,但必须言之成理,能够论述。我觉得高分的关键是自己的view,和相应的好例子,AW考的主要是逻辑和知识面,这以上在官方声明中有明确表述:


some Issue responses at the 6 score level that begin by briefly summarizing the writer's position on the issue and then explicitly announcing the main points to be argued. The readers .know that a writer can earn a high score by giving multiple examples or by presenting a single, extended example.
可见,总结原文观点和背景不要太长!要高度概括!还有可以选择两种方式开展开body,一是view+examples+conclusion,另一个是view(主)+ an example+further view(次)全方位 +conclusion。这种追根究底式的论证思路更能体现到逻辑严密和思路深邃透。但每一个body,都需要有逻辑,应该特别注意逻辑连接词!
   我的主要缺点: 总爱用长篇大论来叙述背景,而到了关键处有一笔带过,舍本逐末,写Body时,没有太强的逻辑,文法还有问题。而且中式作文思想严重——“含蓄”!个人觉得中国人的哲学和老美有很大区别,以前那一套用在老美身上不但不起作用,还会找来中心不明,立意不清的罪名!
  在初期阶段,我想先把独自练习写每一段body,练习逻辑及组织能力。先写好每一段,在慢慢组织全文。平常多读书,开阔视野,提高View的角度。例子也须多积累,但我想不求数量大,主要是深挖掘,把例子活用!
  对于阿狗,我觉得逻辑错误都已成熟,但唯一是模板化太严重,一个body中刨去模板句,自己的东东还剩多少?所以我想在每段的可能情况中再加上些,模板句要有自己的套路和风格,不能亦步亦趋啦!
  以上是我的感想,请组长接收!对上一篇日志深表歉意,没有说到重点,浪费了组长的宝贵时间~





使用道具 举报

Rank: 9Rank: 9Rank: 9

声望
758
寄托币
11696
注册时间
2004-8-28
精华
11
帖子
1564

Taurus金牛座 荣誉版主 AW活动特殊奖 AW作文修改奖 IBT Smart

5
发表于 2009-10-9 20:08:39 |只看该作者
把两篇帖子合一块儿吧~~

intro是精华之中的精华。这也是为什么我们在最初的最初就要求大家去一遍遍的研读。
每一次研读都会对我们所要达到的目的及如何达到它有更清晰的认识。
势必。我还会要求你们再一遍又一遍的读它的~~嘿嘿。
welcome~~
No more words. No more comments.

我想离开。这个浮华的世界。

行走在崩溃的边缘············

使用道具 举报

声望
0
寄托币
14
注册时间
2012-7-26
精华
0
帖子
0
6
发表于 2009-10-13 00:19:56 |只看该作者

【备考日志】草莓酱拌饭小组 BY Donna

本帖最后由 Donna.# 于 2009-10-25 21:16 编辑

今天收到组里的作业,准备吧Economist Debates 部分做一下总结。小的不才,望前辈们多多指教,也希望G友们从中有所启发~
1# about the debate
2# backgroud reading
3# statements( opening)
4# guest ( opening)
5# statements (rebuttal)
6# guest( rebuttal)
7# guest( rebuttal)
8# closing
9# decision
About this debate
Health care
The widespred use of compatative effectiveness reviews and cost/benefit analyses will stifle medical innovation and lead to unacceptable rationing of health care.
backgroud reading
A
Heading for the emergency roomJun 25th 2009 | WASHINGTON, DC
From The Economist print edition
America’s health care is the costliest in the world, yet quality is patchy(not reliable or satisfactory) and millions are uninsured. Incentives for both patients and suppliers need urgent treatmentIllustration by Otto Steininger
NO ONE will be astonished to hear that health care costs more in Indiana than in India. However, a few might be surprised to learn that Americans spend more than twice as much per person on health care as Swedes do. And many may be shocked to be told that in Miami people pay twice as much as in Minnesota, even for far worse care. 同义替换
The American health-care system, which gobbles up about 16% of the country’s economic output, is by far the most expensive in the world (see chart 1). The Congressional Budget Office (CBO) estimates that on current trends spending on Medicare and Medicaid, the government schemes for the old and the poor, will rise from 4% of GDP in 2007 to 12% in 2050. The prospect of long-term fiscal disaster is the main reason why efforts to reform health care are gaining momentum(冲力,动力) in Washington, DC. As Peter Orszag, the director of Barack Obama’s Office of Management and Budget, puts it, “that ‘long term’ keeps getting closer and closer.”

The system has its defenders. They point out that countries should expect to spend more on health care as people age. Americans are wealthy enough to choose extra health care over other things. Their free-spending approach calls forth the invention and speedy adoption of valuable new drugs, devices and procedures, whereas Europe’s stodgy and stingy (not to mention socialist) health-care systems deny coverage and ration care, to the detriment of their people’s health.
A poll carried out for The Economist by YouGov highlights Americans’ beliefs about the state of their system. Although 68% of them rate the care they receive as “excellent” or “good”, 52% are dissatisfied with the quality in the country as a whole. Only 25% think the system works pretty well and requires only minor changes; 40% think fundamental change is needed and 29% think it should be completely rebuilt. Some results are shown in chart 2. A fuller version is available at www.economist.com/yougovpoll.

The doubters have a better case than the defenders. Granted, medical inventions are readily embraced by American doctors and patients. In specific instances—technology to save babies born prematurely and statin drugs to reduce cholesterol, to take two—the benefits of spending greatly outweigh the costs很好的结构. But if the system in general were providing value for money, America’s vast expenditure would at least be reflected in a healthier population than in more frugal countries.先扬后抑,是反对的论证方法

Alas(unfortunate) , it is not. Comparisons with other rich countries and within the United States show that America’s health-care system is not only growing at an unsustainable pace, but also provides questionable value for money and dubious medical care.完美的长句,练写之 Three troubling symptoms stand out: uneven quality of care, inadequate coverage and soaring costs用词精当.

Start with quality. Evidence is mounting that spending more does not necessarily buy better health. (TS)On the contrary, it appears that many Americans are getting mixed or even downright( unpleasant,bad qualities and behaviour)  dreadful health care. In a recent study economists at the OECD found that America does indeed do well on some measures, such as breast-cancer survival rates and cervical-cancer screening, compared with other rich countries. However, it does worse in other areas. American infant mortality was 6.7 per 1,000 births in 2007, against an OECD average (excluding Mexico and Turkey) of 4.0. The death rate after haemorrhagic strokes was 25.5% in American hospitals but only 19.8% in OECD countries as a group.又是先扬后抑,让人更能接受。

Jonathan Skinner, an economist at Dartmouth College, cautions that factors other than health-care systems—attitudes to teenage pregnancy, say, or smoking—may influence the numbers. Even so, he thinks the system is wasteful(kws). In a paper in the Journal of Economic Perspectives last year he and Alan Garber, of Stanford University, argued that America’s health system was “uniquely inefficient”, producing too little per unit of input and consuming far too much of the country’s resources.强对比!语言简练有力!

Mr Skinner is involved with another worrying line of research. The Dartmouth Atlas project has scrutinised(exam sth carefully) variations in health outcomes and spending involving Medicare. It has found wide differences in costs across the country—less than $5,000 per person in Salem, Oregon, in 2006; a bit more than $8,000 in San Francisco, in line with the national average; more than $16,000, and rising fast, in Miami—but no connection between higher spending and better outcomes(TS 呼应). In fact加强例证, the evidence points in the other direction: outcomes tend to be better where costs are lower. Mr Orszag points to the Dartmouth work to argue that up to 30% of America’s health-care spending is sheer waste.(特别喜欢这种修辞,加强积累)
论述第一观点,整体为否定,逐点说明:直接原因不好,深层是浪费,进一步更狠为便宜的倒好。这种论证让人毫无疑义地接受作者的观点!
The second symptom is coverage. Uniquely among rich countries, America’s system of health insurance is not universal. Around 49m people have no health insurance. On current trends, within a decade 60m will be without cover. Studies have shown that not all these people are indigent: a quarter or more can afford insurance, but choose not to buy it.
They know they are unlikely to be left to die in the streets. With the truly poor, the free-riders turn up at emergency rooms. This is hugely inefficient, because pricey late interventions and operations could very often have been avoided with a much smaller investment in preventive care. Insured people and taxpayers are forced to cross-subsidise such “uncompensated” and wasteful treatments to the tune of tens of billions of dollars per year.
Other rich countries cover almost all their citizens in one of two ways. Some, such as Britain, Canada and Sweden, have “single payer” systems, in which taxes support a public service. Others, notably the Netherlands and Switzerland, oblige individuals to buy insurance. France has a mixed public-private system.仅用区区几个词,就让文章流畅
After decades of failed attempts at reform, a consensus appears to be emerging in America around the principles needed for universal coverage. One likely change means a restructuring of America’s failed health-insurance markets. Firms are today allowed to pick the safest patients and reject the sickest. In future they will have to take all comers. Because this imposes unfair burdens on firms that attract lots of older or sicker people, reform is likely to include government-funded mechanisms for risk pooling or reinsurance. The Netherlands, in particular, uses such an approach.
American health insurers, having long opposed this idea, have performed a startling U-turn in recent weeks. America’s Health Insurance Plans, their chief lobbying group, now says it is willing to accept such heavy-handed reforms—if they are accompanied by a requirement that all Americans purchase coverage. This may seem a cynical ploy to expand their business, but some compulsion is needed to get around the selection problem. Any legislation is likely to include subsidies to help the poorest pay for cover.
If done properly,(好语法) this will in time move America towards the Swiss and Dutch models of universal private insurance. These are not perfect, to be sure. Regina Herzlinger of Harvard Business School observes that the Dutch reforms have led to rapid consolidation of insurers and hospitals, fuelling resented price increases. She favours the decentralised(分散) Swiss model, which preserves individual choice and competition. Others note that Swiss health-care costs are high by European standards. But they are a third less, as a share of GDP, than America’s, and the country’s excellent health outcomes should be the envy of American reformers. Our poll suggests that an individual mandate would be unpopular, with only 21% in favour and 53% opposed. Respondents did favour地道啊 having the option to buy from the government, by 56% to 23%.
Such reforms would expand coverage, but could exacerbate the third symptom, cost,不留痕迹地引如KWS as the experience of Massachusetts, a trailblazing领导性的 state that has already implemented贯彻 a plan for universal coverage, suggests. The state faces possible bankruptcy unless it finds a way to rein in costs.
Your money or your life.
Indeed, tackling inflation in American health care remains the most important and difficult part of the treatment. According to our poll, cost is a tender nerve: 61% thought the high cost of care and insurance was a bigger problem than the number of uninsured, against 31% who believed the reverse. Only 21% would be willing to support a reform plan if they had to pay more in insurance or tax; 62% would not.
Some common diagnoses are wide of the mark. One is price gouging by drug companies. In fact, pills account for barely a tenth of health-care spending in America and similarly small shares elsewhere. But aren’t costs lower in Europe because of price controls? Europe does indeed spend less on new branded drugs, but also uses fewer generic drugs and pays much more for them. And Switzerland actually has higher drug prices than America (as does Canada). Greedy drugmakers are not the main cause of America’s runaway costs.
Nor are baby-boomers, though they are often blamed for health-care inflation because there are a lot of them and they are getting old. Ageing will clearly push up costs in time (see our special report in this issue), but it is not the main culprit(offender) yet. The CBO estimates that ageing accounts for only a quarter of the health-care inflation to come in the next few decades, and the share in other rich countries is similar.
Doctors’ generous pay is another popular culprit. But doctors in several European countries are well paid too. The OECD estimates that general practitioners in America earn 3.7 times the average wage. Their British counterparts earn 4.2 times their national average. American specialists earn 5.6 times the average wage, against 7.6 times for their Dutch colleagues. Yet health-care costs in Britain and the Netherlands remain lower than America’s. The real problem is not how much American doctors are paid, but how. The system of medical reimbursement薪金 warps incentives for doctors, insurers and patients that lead Americans to consume more and more medical services.好句子练写 There is strong evidence that Americans use pills, procedures, scans and other expensive forms of health care more often than do patients in other rich countries, and not always to good effect.

America’s insurance system encourages overuse in several ways. One is the tax break that favours health insurance provided by employers, which leads to excessively generous coverage and hence over-consumption. Another is the fact that American health insurers earn a lot of revenue from administering the health plans provided to employees by big corporations which, in effect, insure themselves. This leaves insurers with no incentive to curb抑制 costs, because more spending means fatter management fees.

The incentives facing doctors are even more perverse. Most doctors are not paid a fixed salary, still less rewarded for better health outcomes. Integrated American systems such as Kaiser Permanente and the Mayo Clinic are exceptions to this rule, and Britain’s National Health Service (NHS) is trying to adopt a similar approach. But most doctors and hospitals are paid more if they provide more services, regardless of the results好结构. Predictably, this leads to far higher rates of doctors’ visits, specialist referrals, scans and so on.

For instance, the OECD countries have an average of 11 magnetic-resonance imaging machines per 1m people. America has 25.9. America uses them more often, too: 91.2 times per 1,000 people per year, compared with the OECD average of 39.1. Similar tales can be told about other pricey kit.

This incentive problem even extends to patients. If patients pay very little out of their own pockets they have little desire to curb consumption. Though this is a problem in many OECD countries, in America the proportion of out-of-pocket spending has declined sharply in the past few decades. And a new report by McKinsey, a firm of management consultants, identifies a more subtle problem. Having examined insurance and out-of-pocket spending for several health risks, it concludes that Americans are generally “over-insured and under-saved”. It is prudent for individuals to have comprehensive全面 health insurance against catastrophic health risks such as heart attacks or cancer. But McKinsey finds that Americans with private health insurance often have generous coverage for non-essential and even medically unjustified care (see chart 3). This encourages over-consumption.

The power of sunshine
A second big factor pushing up health costs is the lack of competition among operators of American hospitals. Thanks to a wave of consolidation in recent years, argues Harvard’s Ms Herzlinger, “most parts of the United States are dominated by oligopolistic hospital systems.” 如何漂亮地引用George Halvorson, who heads Kaiser Permanente, insists that “there is an almost total lack of price competition among providers.”

Nimble upstarts and innovators are challenging the incumbents in some areas. Such efforts range from specialist heart hospitals, which get better outcomes at more reasonable prices than local general hospitals, to retail clinics at Wal-Mart stores. Remote medicine, in the form of technology for tele-care or medical tourism to Thailand and Costa Rica, also poses a threat. But medical lobbies are using political influence and outdated regulations to thwart competition where they can (for example, through rules preventing a doctor from treating a patient in another state).

To counter this, reforms could allow federal regulators to overrule(否决) state-level obstacles to entrants such as clinics staffed by inexpensive nurse-practitioners. More transparency would help too, by empowering patients to choose hospitals and doctors providing good value and better results. Electronic medical records would make shopping around easier.

Another useful way to promote transparency and value would be to evaluate the cost-effectiveness of new drugs, devices and treatments. This may be common sense, but it is rarely done in America. Britain’s National Institute for Health and Clinical Excellence (NICE) pioneered this approach, and other European countries have followed it. Andrew Dillon, the agency’s chief executive, accepts that “the NICE model is not transportable in precise form” but he still insists that “one can dissect剖析 and apply what is relevant to other countries.”

In America, the drugs and devices lobbies are violently opposed to a NICE-style agency that could issue mandatory rulings. They paint a scary picture of Americans being denied access to life-saving new drugs by faceless bureaucrats. In Britain NICE has come under fire for rulings that limited access to expensive drugs for Alzheimer’s and cancer on the NHS. America could get around this problem by requiring and perhaps even funding studies, but leaving insurers and individuals to decide whether to pay for treatments.

More competition and transparency would help, but the main goal of any reform plan must be to address重要词 the perverse incentives that encourage overconsumption and drive up costs. Medicare has been tinkering with “pay for performance”, a promising experiment. Mr Halvorson insists that by rejigging incentives other health providers can also create their own “virtual Kaisers”.

If American reformers doubt the power of incentives, they should visit Sweden. Like other relatively cheap OECD systems, Sweden’s single-payer model has been plagued by long waiting-lists—a sign, to American conservatives, of the rationing that goes with socialised medicine. Swedish health officials tried and failed to cut queues by increasing direct funding for hospitals and even issued an edict requiring hospitals to cut queues for elective operations to three months. Then, last year, the health ministry said it would create a fund into which it would pay SKr1 billion ($128m) a year for local authorities that managed to reduce waiting times to that threshold. Nine months ago virtually none of the counties passed, but this month the health minister revealed that nearly all had cut their queues to three months or less.

Anders Knape, the head of the organisation representing county governments, ascribes this to “a dramatic change in incentives”. In the past, he explains, hospital bosses believed waiting lists were a sign of being overloaded, so they tolerated them in the hope of winning more funding. With the new scheme, however, “no queues means more resources”.
在解决问题方面,作者分两点1competition2more transparenty.每点都有面临的挑战和它的好处,有体现了逻辑的严谨性。
If getting incentives right can mobilise even a state-run health system like Sweden’s, surely there is scope for such reforms to fix America’s mess too. If the United States couples its efforts to expand coverage with such a radical restructuring of the underlying drivers of cost inflation, there is every reason to think its health system can become the best in the world—and not merely the priciest.
B
Medicine goes digitalApr 16th 2009
From The Economist print edition
The convergence of biology and engineering is turning health care into an information industry. That will be disruptive, says Vijay Vaitheeswaran (interviewed here), but also hugely beneficial to patientsINNOVATION and medicine go together. The ancient Egyptians are thought to have performed surgery back in 2750BC, and the Romans developed medical tools such as forceps(钳子) and surgical needles. In modern times medicine has been transformed by waves of discovery that have brought marvels like antibiotics(抗生素), vaccines(疫苗) and heart stents(心脏搭桥).

Given its history of innovation, the health-care sector has been surprisingly reluctant to embrace information technology (IT). Whereas every other big industry has computerised with gusto since the 1980s, doctors in most parts of the world still work mainly with pen and paper.
But now, in fits and starts, medicine is at long last catching up. As this special report will explain, it is likely to be transformed by the introduction of electronic health records that can be turned into searchable medical databases, providing a “smart grid” for medicine that will not only improve clinical practice but also help to revive drugs research. Developing countries are already using mobile phones to put a doctor into patients’ pockets. Devices and diagnostics are also going digital, advancing such long-heralded ideas as telemedicine, personal medical devices for the home and smart pills.

The first technological revolution in modern biology started when James Watson and Francis Crick described the structure of DNA (很好的写作素材half a century ago. That established the fields of molecular and cell biology, the basis of the biotechnology industry. The sequencing of the human genome nearly a decade ago set off a second revolution which has started to illuminate the origins of diseases.

The great convergence
Now the industry is convinced that a third revolution is under way: the convergence of biology and engineering. A recent report from the Massachusetts Institute of Technology (MIT) says that physical sciences have already been transformed by their adoption of information technology, advanced materials, imaging, nanotechnology(纳米技术 and sophisticated(精细的)modelling and simulation. Phillip Sharp, a Nobel prize-winner at that university, believes that those tools are about to be brought to bear on biology too.

Robert Langer, a biochemist at MIT who holds over 500 patents in biotechnology and medical technologies and has started or advised more than 100 new companies, thinks innovation in medical technologies is about to take off. Menno Prins of Philips, a Dutch multinational with a big medical-technology division, explains that, “like chemistry before it, biology is moving from a world of alchemy(炼丹术) and ignorance to becoming a predictable, repeatable science.” Ajay Royyuru of IBM, an IT giant, argues that “it’s the transformation of biology into an information science from a discovery science.”这里科学的论述正是Issues中关于research is unclear and controversal,哈哈有一个例子!

This special report will ask how much of this grand vision is likely to become reality. Some of the industry’s optimism appears to be well-founded. As the rich world gets older and sicker and the poor world gets wealthier and fatter, the market for medical innovations of all kinds is bound to grow. Clever technology can help solve two big problems in health care: overspending in the rich world and under-provisioning(食物,供应品) in the poor world.

But the chances are that this will take time, and turn out to be more of a reformation than a revolution. The hidebound health-care systems of the rich world may resist new technologies even as poor countries leapfrog( 跨越)ahead. There is already a backlash against genomics, which has been oversold to consumers as a deterministic science. And given soaring health-care costs, insurers and health systems may not want to adopt new technologies unless inventors can show conclusively that they will produce better outcomes and offer value for money.

If these obstacles can be overcome, then the biggest winner will be the patient. In the past medicine has taken a paternalistic(家长式作风的) stance, with the all-knowing physician dispensing wisdom from on high, but that is becoming increasingly untenable. Digitisation promises to connect doctors not only to everything they need to know about their patients but also to other doctors who have treated similar disorders.
The coming convergence of biology and engineering will be led by information technologies, which in medicine means the digitisation of medical records and the establishment of an intelligent network for sharing those records. That essential reform will enable many other big technological changes to be introduced.

Just as important, it can make that information available to the patients too, empowering them to play a bigger part in managing their own health affairs.句子地道 This is controversial, and with good reason.平衡观点结论句如此之简练!学啊! Many doctors, and some patients, reckon they lack the knowledge to make informed decisions. But patients actually know a great deal about many diseases, especially chronic ones like diabetes and heart problems with which they often live for many years. The best way to deal with those is for individuals to take more responsibility for their own health and prevent problems before they require costly hospital visits. That means putting electronic health records directly into patients’ hands.

使用道具 举报

声望
0
寄托币
14
注册时间
2012-7-26
精华
0
帖子
0
7
发表于 2009-10-13 20:47:50 |只看该作者

【备考日志】草莓酱拌饭小组 BY Donna

本帖最后由 Donna.# 于 2009-10-14 16:32 编辑

读《领悟自由之美-我用满分告诉你写作的"真相"》有感
原文说高分的三点:第一,把题目弄明白,第二,能顺得清楚自己的逻辑,错误找两三个够了,小的说不完,说到最后自己都不知道谁对谁错了.就放掉,第三,造句.用正确的语法,但不强求太复杂,长句少,就像正常说话一样,词汇轻易不要用6级以上的.总的来说一句话,feel free, open your heart and write your own way.
对我而言,第一点我不成问题,逻辑错误我和前辈的一样,找三点主要的、自己能掰扯明白的,这语言我之前一直很注重单词的选择,总想用GRE中的词,生涩的为好,那体现了水平,原来自己一直被骗的那么苦!反倒是重要的语法,我一直是视而不见,抱有基础还可以的啊Q心态!回头看看我做天标注在Economist debates 中的东东,觉得那些才是自己想要的语言和逻辑,可比黄金句型对我有用多啦,也不用死记硬背,because I love them!很喜欢这个作业!
"人家ETS不要求你把里面的每个细致入微的拐来拐去的逻辑论证找出来,人家只要你能找出一条主线,然后自己能整顺溜了,说完整,输入速度别太慢,单词别错太多,就可以了"有对ETS对AW的要求有了一个全新的认识,而且也增长了不少信心哈!
下一步的目标,我要用自己的话写A7,抛弃所用模板,希望我背的那些陈词滥调能早点离去~

使用道具 举报

声望
0
寄托币
14
注册时间
2012-7-26
精华
0
帖子
0
8
发表于 2009-10-13 22:54:27 |只看该作者
本帖最后由 Donna.# 于 2009-10-25 20:30 编辑

  • 0pening statements
  • The moderator's opening remarks
  • As the rich world grows older and sicker and the poor world gets wealthier and fatter, the cost of health care is soaring. Governments and insurers the world over are struggling to cope with runaway health inflation. Adding to the demographic shift in OECD countries and the wealth effect in the emerging giants is the unprecedented wave of technological innovation in new pills, procedures and devices made possible by the ongoing convergence of biology and engineering.
  • The potential health and welfare benefits of this revolution are breathtaking, every bit as much as the wave of innovation that earlier produced vaccines, for example, which are among the most powerful of all health interventions. But the coming grand convergence could, some argue, instead turn into a tale of need versus greed, a conflict between the haves and have nots.插入的用法甚好
  • Even if such a battle royal is not on the cards(可能), the pace of medical innovation and the seemingly insatiable growth in demand for health care certainly raise the question of how to pay for future medical marvels. Some argue that commonsense tests of economics, ranging from cost-benefit analysis to comparative effectiveness reviews, are essential to weed out the worthy from the wasteful. But others argue that such tools are crude and anti-innovation at best(充其量,至多), and, if wielded by stingy governments, implements of cruel health-care rationing (or "death panels", as Sarah Palin, the former Alaskan governor, famously called this) at worst.
  • One of the most prominent voices making the latter case of late has been Newt Gingrich, the former Speaker of America's House of Representatives. In his aggressive opening defence of the motion for our debate, he makes a clear link between comparative effectiveness reviews (CERs) and patient harm: when such tools are "combined with the pressure to control costs and the power to decide who gets what," he insists, "innovation will suffer and patients will suffer."
  • Mr Gingrich's strident arguments appear to flow from a political philosophy, much more commonly expressed in America than in Europe, that emphasises individual rights and choices over collective action or the optimal societal outcome. On his view, a rational health-care future will emphasise personalised therapy疗法)tailored(使...适应) to the genetic needs of the individual, not the number-crunched and coldly utilitarian calculus offered by CERs. The sharp end of his argument is summed up by this simple question: "Do you want the government to decide?"
  • Britain's National Institute for Health and Clinical Excellence (NICE) is a government body that has pioneered the use of CERs and other related policies. Sir Michael Rawlins, its chairman, offers a full-throated defence of that approach as his opening salvo(礼炮) in opposition to the motion. He makes it plain early on that his faith in comparative effectiveness tools flows from a respect for the social compact by posing this revealing rhetorical(花言巧语) question: "On what basis should nations use their resources to treat ill-health in a manner that is fair to all?" This suggests his thinking is more in line with European sensibilities. Defenders of America's individualistic and market-oriented health system often say that it is better and more innovative than its rivals, but few dare to claim that it is "fair to all".
  • Sir Michael insists that the use of CERs has grown into a "sophisticated(复杂的) scientific discipline" that seeks to answer two critical questions: does a new technology offer benefits when compared with existing options, and if so by how much?句子简短,内容俱全,个人认为短句更能有力地表达出思想感情 He points to various case studies, including the increased use of thromolytic technology to treat heart attacks and diminished use of SSRI ('selective serotonin reuptake inhibitors') anti-depressants to treat children, that prove the value of CERs. Taking all the evidence into account, he thunders: "It is inconceivable that any rational person would either object to, or want to stand in the way of, comparative effectiveness reviews." 模棱两可的含蓄表达
  • The topic of our debate is a timely and important one. Our debaters are genuine heavyweights and, as their opening arguments make plain, are spoiling for a fight. The first shots have been fired. Now is the time for you, gentle reader, to weigh in with your vote.

使用道具 举报

声望
0
寄托币
14
注册时间
2012-7-26
精华
0
帖子
0
9
发表于 2009-10-15 22:24:19 |只看该作者
本帖最后由 Donna.# 于 2009-10-26 21:10 编辑

The proposer's opening remarks
In a recent Wall Street Journal column, I told the story of a three-year-old boy who was diagnosed with a rare, aggressive form of bladder(膀胱) cancer. His parents were told that his chance of survival was 50%.
Their options included radical surgery to remove his bladder, prostate(前列腺), and portions of his rectum(直肠). The side effects included impotence(性无能), a colostomy bag, and having to urinate(尿) through a bag in his abdomen. Radiation was also an option, but because he was so young, his pelvic bones and hips would not grow properly, and his bladder would remain the size of a three-year-old's for the rest of his life.
His parents were also told of an "unproven" option: proton beam therapy. Proton beams would target the radiation dose to limit the radiation scatter, which would avoid extensive damage to his body. The targeted beam would also likely be more effective at killing the cancer cells. While the clinical research was insufficient, the physicians' recommendations were unanimous. The boy underwent the treatment. He responded beautifully and is now cancer free, living a normal, healthy life.
Innovation and technology saved his life. Government-imposed comparative effectiveness research did not.
In fact, because there is little science on using proton beam therapy for pediatric cancers, a strict adherence to comparative effectiveness research would probably have led to the boy's death or certainly his mutilation. In most nationalized health systems, his parents would likely have been denied the power to choose this treatment because government-imposed comparative effectiveness research would have deemed it unproven, investigational, or experimental.
As Thomas Kuhn so powerfully explained in his masterwork The Structure of Scientific Revolutions, new science is always unproven at first. But today's breakthroughs regularly become tomorrow's routine treatments. Just look at Lance Armstrong's triple drug combination for metastatic testicular(转移的睾丸) cancer. Many similar innovations were discovered not through population-based research, such as comparative effectiveness, but through personalized application with specific individuals.
That is not to say that population-based research has no role. I have long advocated that knowing whether a treatment, pharmaceutical(药方的), or technology actually works will lead to better health and better quality because individuals could get the right treatment at the right time and not pay the opportunity costs associated with pursuing ineffective treatments. This kind of knowledge can give patients and their families important information to make more informed, individual, and independent decisions with their doctors.
As my friend in this debate, Sir Michael Rawlins, recently said of all the various options to treat prostate cancer, "We're not sure how good any of these treatments are." Sir Rawlins is right that for prostate cancer, and indeed for most treatments, we cannot predict what will work and what will not for specific individuals. However, knowing what works across a large population is not the same as knowing what is best for an individual.
For example, let's say comparative effectiveness research is used to determine the efficacy(功效) of new drug treatments. Population research reveals that drug A works 70 percent of time and drug B works 60 percent of time. A strict adherence to comparative effectiveness would rule drug A the winner. But what if the 30 percent of people who did not respond to drug A did respond to drug B? Or what about the even smaller groups that may have responded best to drug X, Y, or Z? Population-based research is ill-equipped to answer these kinds of questions.列举他因,这段是很好的A段论证方法
Comparative effectiveness often leads to an even more dangerous outcome. When effectiveness is combined with the pressure to control costs and the power to decide who gets what, innovation will suffer and patients will suffer. That is because many see comparative effectiveness as a way for government to allocate scarce medical resources. Sir Rawlins implied as much when he wrote last year: "Countries do not have infinite sums of money to spend on health… The debate is not about whether - but how - healthcare budgets can be most fairly shared out among a country's citizenry."
Governments, like the United Kingdom, use comparative effectiveness to decide what treatments its citizens can get, from diagnostics, laboratories, and imaging to new innovative drugs and therapies. Go back to the example of drug research. What happens when a drug is more effective than another but costs three times as much? To make this decision, government must weigh the costs it will bear with your quality of life. Do you want government to decide that the more expensive drug isn't worth the cost for you to have less pain and suffering?
Government placing a numeric value on an individual's life, such as the quality adjusted life year formula, or placing a value on an individual's quality of life is anathema to the very foundation of the United States. Our Constitution values life as an unalienable right endowed by our Creator. How can you place a numeric value on an unalienable right?
In addition to the restrictions this imposes on individuals accessing care, this has profound implications for creating or discovering the next breakthrough. What good is a new breakthrough if government decides you can't have it? Take the earlier example of proton beam therapy. There are questions whether it is the most effective way to treat prostate cancer, its most common use. If these questions had led to a wide restriction on using it to treat prostate cancer, would doctors have ever had the opportunity to try it as a treatment for pediatric cancer? New science and innovation would be dramatically reduced if innovators and entrepreneurs have little hope of their products reaching patients.
21st century science and innovation is moving toward personalized, individual-centered medicine, like genetics, and away from population-based research, like comparative effectiveness. We need to embrace and encourage ways to understand how a specific individual will respond to a specific treatment, not try to determine the lowest common denominator for everyone. This kind of research will give rise to a rational—not rationed—healthcare system.

使用道具 举报

声望
0
寄托币
14
注册时间
2012-7-26
精华
0
帖子
0
10
发表于 2009-10-15 22:26:20 |只看该作者
The opposition's opening remarks
Over the past 60 years the advances in medicine and public health have been extraordinary. Because of childhood immunisation, diseases like diphtheria and poliomyelitis are now unheard of in developed countries. Modern antimicrobial agents are available to treat scores of infectious diseases. Treatments to control high blood pressure and reduce blood lipids have had a substantial impact on strokes and heart attacks.
Some of the increase in life expectancy over the period has been due to changes in the environment, such as better housing and reduced atmospheric pollution. Other advances have been the result of eliminating useless or even dangerous diagnostic and therapeutic techniques. And some have unquestionably arisen from the efforts of the pharmaceutical, device and diagnostic industries.
This motion, though, has to be considered in today's context and must address three questions. What is "innovation" in health care? How might comparative effectiveness reviews "stifle innovation and lead to unacceptable rationing"? And on what basis should nations use their resources to treat ill health in a manner that is fair to all?
Innovation
There are numerous definitions of innovation and their multiplicity suggests an amorphous concept. I consider innovation in health care, to be a process or a product that has a positive impact on health. An innovation may be modest (incremental innovation), or it may represent a very substantial advance (step-change innovation). Process and product innovation are both equally important.
Past process innovations include the introduction of day-case surgery for cataract extractions and hernia repairs; the use of home, rather than hospital, dialysis for people with chronic kidney failure and, recently, pre-operative checklists to increase patients' safety during surgical operations. Such process innovations have been of considerable value to patients and in most instances have been associated with a reduced financial cost.
Product innovation may be a new medicine, device or diagnostic technique. It may represent a modest albeit useful advance on existing product; or a step change with profound beneficial effects on a particular disease (e.g. Glivec/Gleevec for chronic myeloid leukaemia).
Comparative effectiveness reviews
Outside the United States, comparative effectiveness reviews are known as health technology assessments. These involve a close examination of the clinical effectiveness of a particular health technology (such as an individual, or class of, pharmaceutical). And they may, or may not, include some form of economic assessment.
Assessing the clinical value of a particular health technology by means of a formal comparative effectiveness review has become a sophisticated scientific discipline. It seeks to answer two critical questions. Does the particular technology offer benefits in comparison with existing forms of treatment? And if so, by how much?
Comparative effectiveness reviews have played a major role in the evaluation of numerous pharmaceutical (and other) products. For example, our knowledge and confidence in the use of thrombolytic ("clot busting") therapy, for the treatment of acute heart attacks, owes much to the technique. The dangers of giving SSRI ('selective serotonin reuptake inhibitors') anti-depressants to children and adolescents were identified from careful comparativeness effectiveness reviews. Nor are these reviews confined to looking at patients as a whole: they have been particularly powerful in identifying subgroups of patients who are more or less likely to respond. Recognising which patients will benefit from the use of aspirin in preventing heart attacks is a case in point.

It is inconceivable that any rational person would either object to, or want to stand in the way of, comparative effectiveness reviews. They form the cornerstone of modern evidence-based medicine. Equally, I cannot conceive how these reviews "stifle innovation and lead to inappropriate rationing of health care". On the contrary, they promote rational health care.
Rationing
The amount that a country spends on health care is closely aligned to its gross domestic product. Richer countries can spend more on health care on a per head basis than poorer ones; but all have finite resources and expenditure on one costly component will inevitably deprive other people, with other conditions, of cost-effective care. This is an unavoidable and undeniable fact of life; and some form of rationing is inevitable in every health-care system that operates within finite resources (as most do). The issue is how, not whether, to ration health care.
Some countries ration on the basis of individual wealth, or income, with the rich having access to health care that is denied to the poor. In Europe our health care is based on compassion. We pool our risks; and we try the best we can to look after each other when we are sick. In other words, our health-care systems try to provide services—not, as in America, just to the wealthy or those able to buy health insurance—but to rich and poor alike. By contrast, in Europe, no citizens are denied access to basic health care merely because they are poor.
Whether or not a particular health-care system can afford a specific innovation depends on two factors. What additional benefit does it bring over and above current care? And at what additional cost? The greater the benefit the more likely it is that an innovation will command a higher price. But there are limits to what health-care systems can afford to pay without depriving other people with other diseases of cost-effective care. Hence the necessity of cost-effectiveness analysis in the deployment of health-care resources.
To meet the needs of patients and the public, innovators must therefore provide their products at an affordable cost. If they cannot do so, it is a failure of the innovative process rather than a failure of the need to examine the cost-effectiveness of innovations themselves. Putting it another way, unaffordable innovation is not an innovation.
The innovative process, particularly for pharmaceuticals, has become outrageously and unnecessarily expensive. We live in a time of unparalleled knowledge and understanding about the biological basis of many diseases. It is essential that these discoveries benefit the entire human race rather than just the rich and the powerful. We need affordable innovation.

使用道具 举报

声望
0
寄托币
14
注册时间
2012-7-26
精华
0
帖子
0
11
发表于 2009-10-26 20:17:55 |只看该作者

RE:【备考日志】关于A7及ETS intro的感悟

本帖最后由 Donna.# 于 2009-10-31 21:04 编辑

ETS中关于A的说明,再次读来依然收获良多。。。
1your task is to discuss the logical soundness of the author's case by critically examing the line of reasoning and the use of evidence.
推理的方法是我们要论证其不合理的攻击对象,如以偏概全,错误类比,草率推广等等。至于use of evidence 则主要是调查类的sampling问题。
2you are not asked to discuss whether the statements in the argument are true of accurate, instead, you are being asked whethe conculsions and inferences are validly drawn from the statements.You are not being asked to agree or diagree with the positio stated, insteade, you are being asked to comment on the thinkng that underlies the position stated.You are not being asked to expresss your own views on the subhect being discussed(as you were in the Issue task), instead, you are being asked to evaluate the logical soundness of an argument of another writer
analytical skills displayed in your critique carry great weight in determining your score.
文章中要写点啥一目了然啊!
7 The following appeared in a letter to the editor of the Clearview newspaper.
"In the next mayoral election, residents of Clearview should vote for Ann Green, who is a member of the Good Earth Coalition, rather than for Frank Braun, a member of the Clearview town council, because the current members are not protecting our environment. For example, during the past year the number of factories in Clearview has doubled, air pollution levels have increased, and the local hospital has treated 25 percent more patients with respiratory illnesses. If we elect Ann Green, the environmental problems in Clearview will certainly be solved."


ETS的A审题注意元素

1 读题
   证据,特别申明和结论,没有根据的假设和前提,没有必然联系的结论(跑题)
2 分析术语
   有选择性的解释,分析手法(找他因、反例),前提,结论

如下是第一次作业的分析:
assumption:
Good Earth Coalition really help protect the evrionemt effctively.
Ann Green makes a great contribution to the Good Earth Coalition.
Factories and air pollution levels have something to do with Frank Braun, namely he contributes to  this situation.
analysis:
Frank :the Clearview town council   factories doubles  air pollution increases  25% more patients
                                                               \                                  |                           /

                                                                         Frank count for poor evirionment
Ann : a member of the Good Earth Coalition
in all : envrionmental member will handle these problems and people should elect him.
alternative explanation  or counterexample:
the number of factories in Clearview has doubled   有可能是当地的物质资源丰富,吸引大量的企业。甚至是Frank本不想多建工厂,是政府的其他人促使的。
air pollution levels have increased  有可能是周边的城市对其的污染,或人民生活(汽车、供暖)排放了大量的有害气体。
the local hospital has treated 25 percent more patients with respiratory illnesses   有可能前几年有很多病例没上报,去年监管严格上报,病例增多。
elect Ann Green problems will certainly be solved 有可能其他人比他还能解决这问题。
时间同时性≠因果关系     必然性不一定成立   
开始正文:

  In this argument, the editor recommends that people should elect Ann Green in order to solve the environmental problems. To justify the recommendation, the editor points out that last year the number of factories has doubled simultaneously air pollution increasing, and that local hospital has diagnosed 25 more patients of  respiratory illnesses. However, the editor lies on several groundless assumptions that make the argument specious at best.


   

   In the first place, the editor relies on the premise that Frank cares little for the environment while Ann Green, who is the number of the Good Earth Coalition, indeed plays a critical role in protecting the environment. Perhaps, he might spare no effort to prohibit the government from building more factories when considering the pollution during produce. In fact, it was the other governors who contributed to the boom of factories. Perhaps, the Good Earth Coalition suffers low efficiency and does not work out well, let alone Ann Green’ efforts. Without ruling out these possibilities or others, the editor’s assumption is dubious.


   In the second place, the editor falsely equals the coincidence with causal relationship. The fact that the number of factories has doubled is a little sign of air pollution. It is entirely possible that these increasing factories use high-tech equipments to deal with the pollution effectively, or, these factories are the economy companies which help primary factories reduce pollution. What is more, common sense tells me that the number of cars which produce plenty of toxic gas have increased with the improvement of living standard. If so, even if Frank does agree to build more factories, the editor cannot convince me that factories rather than other factors result in the increased air pollution.


   In the third place, the editor fails to provide sufficient evidence that local hospitals’ report is sustainable. It is most likely that local hospital did not report all the patients suffering respiratory illnesses compared last year. Therefore, the editor unfairly concludes that air pollution has increased merely depend on such insufficient evidence.


    To sum up, the editor’s recommendation is unconvinced in itself. To bolster it, the editor should provide more information about Ann Green’s efforts in Good Earth Coalition, Frank’s opinion on the boom of factories, as well as the condition of factories, especially the increasing ones in last year. To better evaluate the recommendation, we also need to know the information about the real factors causing air pollution and the sufficient evidence about the report from local hospital during many years till now.

使用道具 举报

声望
0
寄托币
14
注册时间
2012-7-26
精华
0
帖子
0
12
发表于 2009-10-26 20:24:04 |只看该作者

读《写作是门艺术,请端正态度》有感

本帖最后由 Donna.# 于 2009-10-27 19:31 编辑

读这篇帖子已经五六遍了,每一次读都有一种醍醐灌顶的感觉!知道自己在一次次地改进复习和写作方法正是一步步地接近作文的高分,任重道远,努力努力啊!
我的主要毛病还是在偏向使用长句子,说话太罗嗦,而且其中的语法还有相当的问题,而且动词掌握的也不地道,确实这一着急有不由自主地用be句型,不要事先假定读者会心领神会你的每一句潜台词。交待完整,限定清晰,这点在论证中一般就会忽视,反过来用它来比较A的论证,也有很好的功效,我发现很多A的错误就是上来一顿假设,和站不住脚的前提。
保持阅读(我指的是规范的英文作品)的习惯。这是写作的永恒真理,我强烈推荐一个阅读的外文网站,上面全是学术的文章和书籍,http://gigapedia.com/ 我在那上面下了好多电子书,唉,苦于时间有限,读的又慢~

使用道具 举报

Rank: 9Rank: 9Rank: 9

声望
616
寄托币
8910
注册时间
2008-8-15
精华
6
帖子
883

荣誉版主 AW活动特殊奖

13
发表于 2009-10-29 22:39:10 |只看该作者
大赞11,12楼思考!

加油!

使用道具 举报

声望
0
寄托币
14
注册时间
2012-7-26
精华
0
帖子
0
14
发表于 2009-10-31 22:02:48 |只看该作者
看了ealain的作业,对我触动很大,我也要每天更新自己的感想,以前总是寻思自己的复习感悟大部分是令人不愉快的,就没想写进去,不过参看了G友的东东,感觉每天写写,既可以方便自己查看进度,也可以复查看看自己的进步。。。在杀G的路上,自己要一步一个脚印的踏实地走啊!
汇报进度:
   1.上两周单词背的不是很好,我昨天把红宝给撕啦,没5个list 为一本,这样就舒服多了,我要两天看一本,而且背红宝不能一次把所有内容都背了,第一遍只看意思,第二遍看同义词、反义词等。。。这样速度还是很快的,我今天就轻松地看了2个list,效果不错!明天要继续2个。
任务:下星期日前我一定要到20list
    2.看debate,平均两天要看两个小时。改的过程不能太细了,影响阅读速度!

使用道具 举报

Rank: 2

声望
8
寄托币
235
注册时间
2009-2-24
精华
0
帖子
4
15
发表于 2009-11-1 09:49:34 |只看该作者
:handshake

使用道具 举报

RE: 【备考日志】草莓酱拌饭小组 BY Donna [修改]
您需要登录后才可以回帖 登录 | 立即注册

问答
Offer
投票
面经
最新
精华
转发
转发该帖子
【备考日志】草莓酱拌饭小组 BY Donna
https://bbs.gter.net/thread-1015205-1-1.html
复制链接
发送
报offer 祈福 爆照
回顶部